| |
|
|
|
Drug Information Association, Tokyo Conference Center – Shinagawa, Area Shinagawa, 1-9-36 Konan, Minato-ku, Tokyo, Japan
Apr 13 2006
The meeting will begin with two keynote presentations from the PMDA and JPMA. Discussions of clinical study circumstances at medical sites, the importance of project management world wide, and the “critical path” led by the US FDA will follow. This session will conclude with a panel discussion.The “Ask the Regulators” session, featuring open discussion between attendees and representatives from regulatory agencies, will take place during the afternoon of the second day. The discussion will encompass two different themes, Pharmacogenomics and Biologics, and R&D Regulation. All questions will be considered in this open forum. This meeting will focus on ways to develop a drug development strategy and how to handle clinical trials. The content will include regulatory issues as well as clinical research itself. A plenary session, which will include a keynote presentation by a drug development specialist and an opening panel discussion, will begin the meeting.
|
|
|
|
|
|
|
|
Organized by:
|
|
Drug Information Association |
|
|
Invited Speakers:
|
|
1)David M. Maola, Esq., Executive Director, Drug Information Association, USA;
2)Theresa Kane Musser, President, Drug Information Association, and Rigel Pharmaceuticals, USA;
3)Takatoshi Sato, Chair, DIA Advisory Council of Japan and HyCLIPS K.K., Japan.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
|
|
Registration:
|
|
http://www.diahome.org/product/9320/06302.pdf
|
|
|
E-mail:
|
|
dia@diahome.org
|
|
|
|
|
|
|
|
|